JPH0359044B2 - - Google Patents
Info
- Publication number
- JPH0359044B2 JPH0359044B2 JP57055539A JP5553982A JPH0359044B2 JP H0359044 B2 JPH0359044 B2 JP H0359044B2 JP 57055539 A JP57055539 A JP 57055539A JP 5553982 A JP5553982 A JP 5553982A JP H0359044 B2 JPH0359044 B2 JP H0359044B2
- Authority
- JP
- Japan
- Prior art keywords
- observed
- osteoarthritis
- patients
- coli
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000006166 lysate Substances 0.000 claims description 15
- 241000588724 Escherichia coli Species 0.000 claims description 8
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 201000008482 osteoarthritis Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 229960000905 indomethacin Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- -1 4-butyl Chemical group 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 231100000229 OECD 452 Chronic Toxicity Study Toxicity 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000008747 mitogenic response Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/251,549 US4322405A (en) | 1981-04-06 | 1981-04-06 | Method for treating rheumatoid arthritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS57176912A JPS57176912A (en) | 1982-10-30 |
| JPH0359044B2 true JPH0359044B2 (enExample) | 1991-09-09 |
Family
ID=22952441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57055539A Granted JPS57176912A (en) | 1981-04-06 | 1982-04-05 | Deformed arthritis remedy |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US4322405A (enExample) |
| JP (1) | JPS57176912A (enExample) |
| IT (1) | IT1148158B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2550707B1 (fr) * | 1983-08-17 | 1986-02-28 | Lipha | Medicament immunomodulateur d'origine biologique et son procede de preparation |
| US4628052A (en) * | 1985-05-28 | 1986-12-09 | Peat Raymond F | Pharmaceutical compositions containing dehydroepiandrosterone and other anesthetic steroids in the treatment of arthritis and other joint disabilities |
| JP2001511187A (ja) * | 1997-02-28 | 2001-08-07 | エンゾー セラピュウティクス， インコーポレイテッド | 選択的免疫ダウンレギュレーション（ｓｉｄｒ）を行う新規プロセス |
| US7582670B2 (en) * | 2001-12-13 | 2009-09-01 | Natrogen Therapeutics, Inc. | Methods of treating an inflammatory-related disease |
| US8563525B2 (en) | 2004-01-12 | 2013-10-22 | Natrogen Therapeutics International, Inc. | Methods of treating an inflammatory-related disease |
| US20050154046A1 (en) * | 2004-01-12 | 2005-07-14 | Longgui Wang | Methods of treating an inflammatory-related disease |
| CN101426268B (zh) * | 2007-11-02 | 2010-08-25 | 大唐移动通信设备有限公司 | 导频资源分配方法、系统和设备 |
| US12268718B2 (en) * | 2012-01-16 | 2025-04-08 | Labyrinth Holdings Llc | Control of cellular redox levels |
| AU2013209887B2 (en) | 2012-01-16 | 2021-02-18 | Elizabeth Mckenna | Compositions and methods for the treatment of hepatic diseases and disorders |
| US20140086849A1 (en) | 2012-09-21 | 2014-03-27 | Elizabeth McKenna | Naturally-Occurring CpG Oligonucleotide Compositions and Therapeutic Applications Thereof |
-
1981
- 1981-04-06 US US06/251,549 patent/US4322405A/en not_active Expired - Lifetime
-
1982
- 1982-04-02 IT IT48156/82A patent/IT1148158B/it active
- 1982-04-05 JP JP57055539A patent/JPS57176912A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| IT1148158B (it) | 1986-11-26 |
| IT8248156A0 (it) | 1982-04-02 |
| US4322405A (en) | 1982-03-30 |
| JPS57176912A (en) | 1982-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6277836B1 (en) | Methods and compositions for treating inflammatory bowel disease | |
| Dau et al. | Plasmapheresis and immunosuppressive drug therapy in scleroderma | |
| EP1484059B1 (en) | Antiviral compositions comprising phenylacetic acid derivatives | |
| RU96108290A (ru) | Лекарственный препарат и способ профилактики и лечения урогенитальных инфекций | |
| CN1505505A (zh) | 辅酶q作为活性成分的经粘膜给药的组合物 | |
| US4322405A (en) | Method for treating rheumatoid arthritis | |
| CA2274510A1 (en) | Treatment of osteoarthritis by administering poly-n-acetyl-d-glucosamine | |
| JPH09500640A (ja) | 腫瘍壊死因子（ｔｎｆ）の生成抑制及び／又は敗血性ショックの治療のためのキノリン−３−カルボキシアミド化合物の使用 | |
| Girod et al. | The COX inhibitors indomethacin and meloxicam exhibit anti-emetic activity against cisplatin-induced emesis in piglets | |
| US6132715A (en) | Method of inhibiting biosynthesis of tumor necrosis factor | |
| WO2023134202A1 (zh) | 脆弱拟杆菌荚膜多糖a与免疫检查点抑制剂联用在制备治疗消化系统肿瘤药物中的应用 | |
| JPH08502295A (ja) | 悪液質の治療およびｉｌ−６活性の阻害 | |
| JPH0475205B2 (enExample) | ||
| KATAE | Erythromycin the application to streptococcal infections in yellowtails | |
| NL8105635A (nl) | Geneesmiddel met transplantaatafstotings- en/of immunologische ontstekingsremmende werking, alsmede werkwijze voor de remming van transplantaatafstoting en/of immunologische ontsteking. | |
| Decker | Azathioprine and cyclophosphamide as slow-acting drugs for rheumatoid arthritis | |
| KR20120052201A (ko) | ｐ40 의존형 질환의 치료에서 벤지다민의 용도 | |
| FR2663539A1 (fr) | Utilisation de la d-fenfluramine pour l'obtention de medicaments destines au traitement des deficiences immunitaires chez le sujet age. | |
| US6242415B1 (en) | Mediation of cytokines by melanin | |
| JP2848634B2 (ja) | 免疫抑制作用を有する医薬 | |
| JPH07267867A (ja) | 抗内毒素作用を有する治療用薬剤 | |
| Veys et al. | Immunopharmacologic therapy of connective tissue diseases | |
| RU2228742C2 (ru) | Способ лечения рецидивирующего иридоциклохориоидита лошадей | |
| CN117442608A (zh) | 化合物u1158在治疗红斑狼疮中的应用 | |
| Craig | The place of potentiated trimethoprim in the therapy of diseases of the skin in dogs and cats |